Warnex Inc.  

(Public, CVE:WNX.H)   Watch this stock  
Find more results for CVE: wnx
0.100
0.000 (0.00%)
Jun 14 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.18
Open     -
Vol / Avg. 0.00/4,293.00
Mkt cap 2.83M
P/E     -
Div/yield     -
EPS -0.06
Shares 28.32M
Beta 2.29
Inst. own     -
Aug 26, 2013
Q2 2013 Warnex Inc Earnings Release Add to calendar
Jun 3, 2013
Q1 2013 Warnex Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin 5.41% 2.29%
Operating margin 5.41% 8.04%
EBITD margin - 0.36%
Return on average assets 10.18% 4.21%
Return on average equity 43.37% 18.20%
Employees 250 -
Carbon Disclosure Rating - -

Address

3885 Industriel Blvd.
LAVAL, QC H7L 4S3
Canada
+1-450-6636724 (Phone)
+1-450-6692784 (Fax)

Website links

External links

Description

Warnex Inc. is a life sciences company engaged in providing diverse laboratory services. The Company offers analytical and bioanalytical services to the pharmaceutical sector. Its analytical Services provide quality control services to the pharmaceutical and biotechnology industries, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Its bioanalytical Services assists both innovator and generic pharmaceutical companies, as well as biotechnology companies in their development of new pharmaceutical products by conducting bioavailability and bioequivalence studies. On December 8, 2011, the Company sold the assets of its Medical Laboratories division to Gamma-Dynacare Medical Laboratories. In April 2012, it sold its Analytical Services division to NEOPHARM LABS Inc. On December 10, 2012, the Company sold its Bioanalytical Services division to Biotrial Research S.A.S.

Officers and directors

Michael Singer Independent Chairman of the Board
Age: 48
Sean Karamchandani Interim Chief Executive Officer, Chief Financial Officer, Director
Michael Mancini President - Warnex Bioanalytical Services
Joseph A. Walewicz CFA Independent Director
Age: 43